

Miles Parkes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5490720/miles-parkes-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

34,652
citations

58
h-index

159
g-index

159
ext. papers

39,938
ext. citations

15.6
avg, IF

7.47
L-index

#	Paper	IF	Citations
151	Rectovaginal Fistula in Crohn's Disease: When and How to Operate?. <i>Clinics in Colon and Rectal Surgery</i> , 2022 , 35, 10-20	2.3	
150	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	10
149	Single-cell genomics for resolution of conserved bacterial genes and mobile genetic elements of the human intestinal microbiota using flow cytometry.. <i>Gut Microbes</i> , 2022 , 14, 2029673	8.8	0
148	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis.. <i>Nature Communications</i> , 2022 , 13, 2299	17.4	0
147	Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. <i>Gut</i> , 2021 , 70, 677-686	19.2	14
146	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021 , 53, 1543-1552	36.3	11
145	Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. <i>Gut</i> , 2021 ,	19.2	8
144	How do we predict a patient's disease course and whether they will respond to specific treatments?. <i>Gastroenterology</i> , 2021 ,	13.3	2
143	Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2700-2711	4	1
142	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 218-224	18.8	54
141	A Crohn's disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	1
140	Moving towards more patient-centred clinical trials in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 673-674	24.2	0
139	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 800-812	1.5	5
138	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. <i>Efficacy and Mechanism Evaluation</i> , 2021 , 8, 1-88	1.7	
137	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome.. <i>Cell Genomics</i> , 2021 , 1, None		2
136	Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom. <i>Journal of Crohn's and Colitis</i> , 2020 ,	1.5	5
135	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. <i>Nature Communications</i> , 2020 , 11, 995	17.4	21

134	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020 , 33, 170-177	2.2	7
133	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020 , 158, 189-199	13.3	117
132	Personalised medicine in Crohn's disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 80-92	18.8	15
131	Somatic Evolution in Non-neoplastic IBD-Affected Colon. <i>Cell</i> , 2020 , 182, 672-684.e11	56.2	50
130	Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. <i>Gut Microbes</i> , 2020 , 11, 405-420	8.8	24
129	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020 , 69, 984-990	19.2	159
128	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019 , 68, s1-s106	19.2	557
127	Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019 , 19, 82	3	12
126	Genetic and Genomic Markers for Prognostication 2019 , 323-331		
125	Microscopic colitis. <i>Medicine</i> , 2019 , 47, 388-390	0.6	1
124	A blood-based prognostic biomarker in IBD. <i>Gut</i> , 2019 , 68, 1386-1395	19.2	69
123	Diverticular disease: picking pockets and population biobanks. <i>Gut</i> , 2019 , 68, 769-770	19.2	0
122	Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. <i>Immunity</i> , 2019 , 50, 1099-1114.e10	32.3	71
121	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 341-353	18.8	224
120	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. <i>BMJ Open</i> , 2019 , 9, e023765	3	17
119	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 773-783	27.4	75
118	IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis. <i>Gut</i> , 2019 , 68, 1537-1540	19.2	9
117	IBD Genomic Risk Loci and Overlap with Other Inflammatory Diseases 2019 , 91-115		

116	Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease. <i>BMC Gastroenterology</i> , 2019 , 19, 11	3	5
115	The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 583-592	4.5	28
114	Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1011-1015	4	6
113	Patients with perianal Crohn's fistulas experience delays in accessing anti-TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres. <i>Colorectal Disease</i> , 2018 , 20, 797-803	2.1	6
112	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 562-574	9.2	51
111	PRedicting Outcomes For Crohn's disease using a moLEcular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. <i>BMJ Open</i> , 2018 , 8, e026767	3	27
110	On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 5-6	4	
109	Debate session: So what causes inflammatory bowel disease? It's all in the genes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 23	4	
108	Selectively targeting the gut in inflammatory bowel disease: Targeting integrins. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33 Suppl 3, 26	4	
107	Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. <i>Nature Genetics</i> , 2017 , 49, 262-268	36.3	182
106	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017 , 49, 256-261	36.3	462
105	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. <i>Nature Genetics</i> , 2017 , 49, 186-192	36.3	104
104	Defective ATG16L1-mediated removal of IRE1 α drives Crohn's disease-like ileitis. <i>Journal of Experimental Medicine</i> , 2017 , 214, 401-422	16.6	109
103	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 150-161	6.1	46
102	Fine-mapping inflammatory bowel disease loci to single-variant resolution. <i>Nature</i> , 2017 , 547, 173-178	50.4	311
101	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 335-341	1.5	14
100	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet, The</i> , 2016 , 387, 156-67	40	449
99	Genome-wide rare copy number variation screening in ulcerative colitis identifies potential susceptibility loci. <i>BMC Medical Genetics</i> , 2016 , 17, 26	2.1	10

98	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 149-58	1.5	57
97	Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 910-923	6.1	59
96	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. <i>Nature Genetics</i> , 2016 , 48, 510-8	36.3	404
95	Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. <i>Scientific Reports</i> , 2016 , 6, 26747	4.9	19
94	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016 , 98, 857-868	11	14
93	Pooled sequencing of 531 genes in inflammatory bowel disease identifies an associated rare variant in BTNL2 and implicates other immune related genes. <i>PLoS Genetics</i> , 2015 , 11, e1004955	6	43
92	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. <i>Nature Genetics</i> , 2015 , 47, 979-986	36.3	1278
91	Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. <i>Gut</i> , 2015 , 64, 250-9	19.2	24
90	Microscopic colitis. <i>Medicine</i> , 2015 , 43, 291-292	0.6	
89	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. <i>Nature Genetics</i> , 2015 , 47, 172-9	36.3	201
88	Disease-specific alterations in the enteric virome in inflammatory bowel disease. <i>Cell</i> , 2015 , 160, 447-60	56.2	696
87	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014 , 46, 1131-4	36.3	130
86	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1313-23	6.1	43
85	'High definition': not all it appears. <i>Gut</i> , 2014 , 63, 863-4	19.2	
84	A comparison of outcomes for adults and children undergoing resection for inflammatory bowel disease: is there a difference?. <i>ISRN Gastroenterology</i> , 2014 , 2014, 410753		8
83	Genetic insights into common pathways and complex relationships among immune-mediated diseases. <i>Nature Reviews Genetics</i> , 2013 , 14, 661-73	30.1	394
82	Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. <i>Gastroenterology</i> , 2013 , 145, 339-47	13.3	125
81	Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. <i>Cell</i> , 2013 , 155, 57-69	56.2	168

80	Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. <i>Nature</i> , 2013 , 498, 232-5	50.4	156
79	Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. <i>PLoS Genetics</i> , 2013 , 9, e1003723	6	149
78	Personalised medicine and genetic prediction--are we there yet?. <i>Clinical Medicine</i> , 2013 , 13 Suppl 6, s62-4	1.9	
77	DNA methylation analysis in the intestinal epithelium-effect of cell separation on gene expression and methylation profile. <i>PLoS ONE</i> , 2013 , 8, e55636	3.7	22
76	The Genetics of Crohn's Disease 2013 , 99-118		
75	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012 , 491, 119-24	50.4	3239
74	Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. <i>Digestive Diseases</i> , 2012 , 30, 330-3	3.2	39
73	Mucosal genome-wide methylation changes in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2128-37	4.5	103
72	Immuno-inhibitory PD-L1 can be induced by a peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations. <i>Clinical Immunology</i> , 2012 , 143, 162-9	9	20
71	Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012 , 44, 1294-301	36.3	347
70	The genetics universe of Crohn's disease and ulcerative colitis. <i>Digestive Diseases</i> , 2012 , 30 Suppl 1, 78-81	3.2	21
69	Analysis of Interaction for Identifying Causal Mechanisms. <i>Wiley Series in Probability and Statistics</i> , 2012 , 192-207	1.3	2
68	The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: long term outcomes. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 91-4	1.5	19
67	Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. <i>Nature Genetics</i> , 2011 , 43, 1066-73	36.3	584
66	A rare cause of duodenal stricture. <i>BMJ Case Reports</i> , 2011 , 2011,	0.9	1
65	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011 , 43, 246-52	36.3	1028
64	Microscopic colitis. <i>Medicine</i> , 2011 , 39, 237-238	0.6	1
63	New IBD genetics: common pathways with other diseases. <i>Gut</i> , 2011 , 60, 1739-53	19.2	418

62	Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1387-91	4.5	51
61	Genome-wide association studies and Crohn's disease. <i>Briefings in Functional Genomics</i> , 2011 , 10, 71-6	4.9	38
60	Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4170-9	15.9	192
59	Crohn disease: a current perspective on genetics, autophagy and immunity. <i>Autophagy</i> , 2011 , 7, 355-74	10.2	84
58	Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. <i>PLoS Genetics</i> , 2011 , 7, e1001273	6	383
57	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. <i>Nature Genetics</i> , 2011 , 44, 3-5	36.3	39
56	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010 , 464, 713-20	50.4	639
55	Meta-analysis and imputation refines the association of 15q25 with smoking quantity. <i>Nature Genetics</i> , 2010 , 42, 436-40	36.3	521
54	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 1118-25	36.3	1946
53	Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. <i>Nature Genetics</i> , 2009 , 41, 1330-4	36.3	411
52	Common variants at five new loci associated with early-onset inflammatory bowel disease. <i>Nature Genetics</i> , 2009 , 41, 1335-40	36.3	389
51	Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. <i>Gastroenterology</i> , 2009 , 136, 523-9.e3	13.3	152
50	Symptom classification in irritable bowel syndrome as a guide to treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 796-803	2.4	8
49	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. <i>Nature Genetics</i> , 2008 , 40, 710-2	36.3	353
48	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. <i>Nature Genetics</i> , 2008 , 40, 955-62	36.3	2092
47	Use of sirolimus (rapamycin) to treat refractory Crohn's disease. <i>Gut</i> , 2008 , 57, 1294-6	19.2	100
46	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. <i>Autophagy</i> , 2008 , 4, 151-75	10.2	1920
45	Genetics of inflammatory bowel disease: clues to pathogenesis. <i>British Medical Bulletin</i> , 2008 , 87, 17-30	5.4	47

44	Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 733-7	4.5	56
43	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. <i>Journal of Medical Genetics</i> , 2008 , 45, 36-42	5.8	37
42	Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. <i>PLoS Medicine</i> , 2008 , 5, e239	11.6	58
41	Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1259-67	0.7	233
40	IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. <i>Gastroenterology</i> , 2007 , 132, 1657-64	13.3	156
39	Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: lessons for study design. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 1554-60	4.5	12
38	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007 , 39, 1329-37	36.3	1130
37	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2007 , 39, 830-2	36.3	933
36	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007 , 447, 661-78	50.4	7801
35	Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn's disease. <i>Tissue Antigens</i> , 2007 , 69, 236-41		25
34	A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 421-30	6.1	25
33	Microscopic colitis. <i>Medicine</i> , 2007 , 35, 290-291	0.6	1
32	Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. <i>Autophagy</i> , 2007 , 3, 649-51	10.2	119
31	Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. <i>Gut</i> , 2007 , 56, 1489-92	19.2	21
30	Evidence for association of OCTN genes and IBD5 with ulcerative colitis. <i>Gut</i> , 2006 , 55, 809-14	19.2	78
29	Systematic review: the use of mesalazine in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 841-55	6.1	84
28	Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 178-84	4.5	31
27	Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 967-71	4.5	24

26	Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. <i>Journal of Cell Science</i> , 2004 , 117, 1989-99	5.3	78
25	The genetics of inflammatory bowel disease. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 599-602		3
24	Mobilisation of enterocyte fat stores by oral glucose in humans. <i>Gut</i> , 2003 , 52, 834-9	19.2	114
23	Review article: the management of severe Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 563-73	6.1	11
22	Ulcerative colitis is more strongly linked to chromosome 12 than Crohn's disease. <i>Gut</i> , 2001 , 49, 311	19.2	3
21	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. <i>Gastroenterology</i> , 2001 , 120, 834-40	13.3	39
20	Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity. <i>Inflammatory Bowel Diseases</i> , 2000 , 6, 165-70	4.5	19
19	The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. <i>American Journal of Human Genetics</i> , 2000 , 67, 1605-10	11	73
18	Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. <i>Human Molecular Genetics</i> , 1999 , 8, 307-11	5.6	65
17	Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. <i>Clinical and Experimental Immunology</i> , 1998 , 113, 28-32	6.2	41
16	Molecular genetics of Crohn's disease: recent advances. <i>The European Journal of Surgery</i> , 1998 , 164, 887-91		2
15	Genetics of inflammatory bowel disease. <i>Clinical Science</i> , 1998 , 94, 473-8	6.5	40
14	Genetics of inflammatory bowel disease. A personal view on progress and prospects. <i>Digestive Diseases</i> , 1998 , 16, 370-4	3.2	7
13	Two-Stage Genome-Wide Search in Inflammatory Bowel Disease: Strong Evidence for Susceptibility LOCI on Chromosomes 3, 7 and 12. <i>Clinical Science</i> , 1997 , 93, 18P-19P		
12	Mapping susceptibility loci in inflammatory bowel disease: why and how?. <i>Trends in Molecular Medicine</i> , 1997 , 3, 546-53		6
11	Susceptibility loci in inflammatory bowel disease. <i>Lancet, The</i> , 1996 , 348, 1588	40	54
10	Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. <i>Nature Genetics</i> , 1996 , 14, 199-202	36.3	600
9	Cytokine gene polymorphisms in inflammatory bowel disease. <i>Gut</i> , 1996 , 39, 705-10	19.2	90

8 Genetics [Clinical and Therapeutic Applications]85-88

7	Association mapping of inflammatory bowel disease loci to single variant resolution	12
6	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease	4
5	Exploring the genetic architecture of inflammatory bowel disease by whole genome sequencing identifies association at ADCY7	3
4	HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy	10
3	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in a complex disease	2
2	Which will take us Further in IBD? Study of Coding Variation or Epigenetics?1-6	
1	Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility	2